newsfilter
← Latest News
GlobeNewswire·

Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV

Continuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCsAdjusting cost structure to fund operations...